The therapeutic modulation of SIRT7 through inhibitors that stabilize its expression and block pro-tumorigenic pathways may provide a novel approach to controlling pancreatic cancer progression, particularly in cases resistant to conventional therapies. This evidence concerns the gene SIRT7 and pancreatic neoplasm.